Complications of copd exacerbation

How Serious Is COPD

COPD is the third leading cause of death by disease in the United States. More than 15.3 million people have been diagnosed with COPD, but millions more may have the disease without even knowing it. COPD causes serious long-term disability and early death. At this time there is no cure, and the number of people dying from COPD is growing.

COPD in Women

Deaths resulting from COPD in women are higher than in men. There are a few reasons why this happens.

  1. In the late 1960s, the tobacco industry intensely targeted women. This resulted in a huge increase in women smoking. We are still seeing new cases of smoking related diseases, including COPD, as women age.
  2. Women are more vulnerable than men to lung damage from cigarette smoke and other pollutants. Their lungs are smaller and estrogen may play a role in worsening lung disease.
  3. Women are often misdiagnosed. Because COPD has long been thought of as a man’s disease, many doctors still do not expect to see it in women and miss the proper diagnosis.

Learn more about the rise of COPD in women

Missing the Warning Signs

COPD is often not found until the disease is very advanced because people do not know the early warning signs. Sometimes people think they are short of breath or less able to take part in their normal activities because they are “just getting older.”

It Can Be Treated

There’s no cure for COPD, but the good news is that it can be found early. Much can be done to treat and help manage the disease. Through medications, oxygen therapy, pulmonary rehabilitation and social support, many people are able to live with their disease for many years.

Case

A 55-year-old man with hypertension, hyperlipidemia, and chronic obstructive pulmonary disease (COPD) secondary to a 45 pack-year history presents with cough, wheezing, and dyspnea at rest. He reports some mild chest pain that began with his symptoms last week. An electrocardiogram shows inferior q-waves suggestive of a previous myocardial infarction (MI).

Physical examination in the emergency department reveals normal heart sounds, laterally displaced point of maximal impulse (PMI), and no jugular vein distention. On auscultation of the lungs, there is bilateral expiratory wheezing without crackles. Lower extremities are dry without edema. Vitals and laboratory results are normal except for an elevated white blood cell count and high sensitivity C-reactive protein. Troponin test was negative. Chest radiograph showed bilateral lower lobe infiltrates but no edema. He is given albuterol/ipratropium nebulizer treatments and intravenous steroids.

A medical student is curious about the inferior Q-waves seen on the electrocardiogram.

Which of the following most likely increases the risk for MI in this patient?

A. Use of long acting beta-agonists

B. Inhaled steroid use

C. A COPD exacerbation due to increased platelet reactivity

D. COPD due to increased systemic inflammation

E. Both C and D are correct

Are you sure your patient has chronic obstructive pulmonary disease? What should you expect to find?

  • Chronic obstructive pulmonary disease (COPD) is characterized by the progressive development of airflow limitation that is not fully reversible. COPD is comprised of chronic bronchitis and emphysema. The pathology of COPD is an abnormal inflammatory response by the lungs to inhaled noxious particles or gases. It is the fourth leading cause of chronic morbidity and mortality in the United States. COPD exacerbations are defined as “an event in the natural course of the disease characterized by a change in the patient’s baseline dyspnea, cough, and/or sputum that is beyond normal day to day variations, is acute in onset, and may warrant a change in regular medications in a patient with underlying COPD.” COPD exacerbations are associated with increased airway and systemic inflammation. Many COPD exacerbations are due to upper respiratory tract viral infections and environmental factors, such as pollution and weather. COPD exacerbations are a common cause of admission to hospitals and can affect a patient’s functional status, morbidity, and mortality. Lung function after a COPD exacerbation may not recover after 3 months. As the severity of underlying COPD progresses, the frequency and severity of COPD exacerbations increases.

  • Increased shortness of breath is the main symptom of an exacerbation. Other common symptoms include wheezing, chest tightness, increased cough and sputum, change in the color of sputum, and fever. Nonspecific complaints include tachycardia, tachypnea, malaise, insomnia, sleepiness, fatigue, depression, and confusion. Airway inflammation causes airway edema, bronchospasm, and increased sputum production, which can lead to worsening airflow limitation and hyperinflation, which is the main cause of dyspnea. Eliciting history of dyspnea, sputum volume, and sputum purulence has implication for antibiotic therapy.

  • Tachypnea, signs of prolonged expiration (pursed lip breathing), wheezing, crackles, use of accessory muscles, confusion, and new onset cyanosis are key physical findings.

How did the patient develop chronic obstructive pulmonary disease? What was the primary source from which the infection spread?

  • COPD exacerbations are associated with increased airway and systemic inflammation. They are caused by complex interactions between the host, respiratory viruses, airway bacteria, and environmental pollution. They are frequently triggered by upper respiratory infections, especially during winter months. Rhinovirus is the most common virus associated with a COPD exacerbation. Other viral pathogens isolated from patients with COPD exacerbations are coronarvirus, respiratory syncytial virus, influenza, parainfluenza, and adenovirus.

  • The influenza vaccine has decreased the number of exacerbations caused by influenza. COPD exacerbations caused by respiratory viruses have been found to be more severe, associated with longer recovery times, associated with greater falls in lung function, associated with higher airway inflammation, and have more chance of hospital admission than exacerbations without respiratory viruses detected.

  • The role of bacteria in COPD exacerbations is confounded by the fact that airway bacterial colonization in the stable state is associated with the same organism as those isolated during exacerbations. Pathogenic bacteria have been found in the distal airways in 30-50% of exacerbations at bronchoscopy. The most common bacterial pathogens isolated from patients with COPD exacerbations are Haemophilus influenzae, Moraxella catarrhalis, Streptococcus pneumoniae, and Pseudomonas aeruginosa. Purulent sputum is a marker of bacterial infection, as COPD exacerbations associated with purulent sputum are more likely to produce positive bacterial cultures. It is controversial whether atypical bacteria, such as chlamydia, legionella, and mycoplasma, can be implicated in COPD exacerbations.

  • Environmental pollution, such as ozone, particulates, sulfur dioxide, and nitrogen dioxide, can lead to increased COPD exacerbations.

Which individuals are of greater risk of developing chronic obstructive pulmonary disease?

  • COPD exacerbations become more frequent and more severe as the severity of underlying COPD increases. The most reliable predictor of COPD exacerbations appears to be a history of having exacerbations. Common causes of COPD include cigarette smoking, air pollution, airway hyperresponsiveness, and alpha 1 antitrypsin deficiency.

Beware: there are other diseases that can mimic chronic obstructive pulmonary disease:

  • The differential diagnosis of COPD exacerbations includes pneumonia, congestive heart failure, pneumothorax, pleural effusion, pulmonary embolism, and cardiac arrhythmia.

What laboratory studies should you order and what should you expect to find?

Results consistent with the diagnosis

  • An arterial blood gas indicating a PaO2 less than 60 and/or a SaO2 less than 90% with or without a PaCO2 greater than 50 indicates respiratory failure. Moderate to severe acidosis (pH < 7.36) plus hypercapnea (PaCO2 > 45-60) is an indication for mechanical ventilation.

  • The C-reactive protein (CRP) was studied as a biomarker for COPD exacerbations and was found to be neither sufficiently sensitive nor specific alone. The combination of CRP with any increased major exacerbation symptom, such as dyspnea, sputum volume, or sputum purulence, increased the sensitivity and specificity.

What imaging studies will be helpful in making or excluding the diagnosis of chronic obstructive pulmonary disease?

  • A chest x-ray (preferably PA and lateral) is useful in identifying alternative diagnoses. An EKG can assist in diagnosing right ventricular hypertrophy, arrhythmias, and ischemia. Chest CT is specific for diagnosing COPD and identifying bullae but does not provide much information in diagnosing a COPD exacerbation. Spirometry is not recommended during an acute exacerbation, as it can be difficult for a sick patient to perform the test properly.

What consult service or services would be helpful for making the diagnosis and assisting with treatment?

If you decide the patient has chronic obstructive pulmonary disease, what therapies should you initiate immediately?

  • Pulmonary consultation may beneficial for further management of COPD exacerbations. ICU services are warranted when patients develop respiratory failure.

  • It is important to consider the cause of the exacerbation, the degree of reversible bronchospasm, recent drug use, and contraindications to treatment when initiating therapy. Evaluation of the airway and breathing should be the primary goal to determine whether noninvasive or invasive ventilation is needed. An Inhaled beta-2 agonist with or without an inhaled anticholinergic should be delivered via spacer or nebulizer. Corticosteroids can be administered intravenously. Antibiotics can be administered if it thought that the patient has an intercurrent infection.

1. Anti-infective agents

If I am not sure what pathogen is causing the infection, what anti-infective should I order?

Antibiotics given at exacerbations can offer a small but significant benefit in treatment failure and mortality. Use of antibiotics is indicated in patients with all three of the major symptoms of increased dyspnea, sputum volume, and sputum purulence; two of the three major symptoms, of which one is sputum purulence; and exacerbations requiring invasive or noninvasive mechanical ventilation. Antibiotic benefit is greatest in patients with more severe disease.

Empiric treatment requires knowledge of local bacterial prevalence and microbiological guidance. Antimicrobial therapy should be tailored to sputum culture sensitivity results. Concerns about resistant flora have prompted some physicians to use broader spectrum antibiotics empirically, but no evidence supports the first line use of such agents. In studies evaluating the efficacy of antibiotic treatment, tetracycline, amoxicillin, and trimethoprim-sulfamethaxozole were the most common antibiotics and treatment duration ranged from 3 to 14 days. The emergence of increasing resistance, especially among S. pneumoniae, has prompted the use of broader spectrum antibiotics.

One algorithm proposes no antibiotics for mild COPD exacerbations (<1 cardinal symptom). For moderate or severe COPD exacerbations (at least two of three cardinal symptoms), risk factors of age older than 65 years of age, FEV1 less than 50% of predicted, three or more exacerbations, and presence of cardiac disease should be considered. Antibiotic selection in simple COPD exacerbations (no risk factors) include macrolides (azithromycin, clarithromycin), cephalosporins, (cefuroxime, cefpodoxime, cefdinir), ketolide (telithromycin), doxycycline, and trimethoprim-sulfamethaxazole. Antibiotic selection for complicated COPD (1 or more risk factors) includes fluoroquinolones (moxifloxacin, gemifloxacin, levofloxacin), amoxicillin/clavunate, and ciprofloxacin if there is risk for Pseudomonas. A different antibiotic class should be selected if there was recent antibiotic exposure within 3 months.

In hospitalized patients, patients with risk factors for Pseudomonas should be treated with levofloxacin, cefepime, ceftazidime, or piperacillin-tazobactam after a sputum gram stain and culture are performed. Patients without risk factors for Pseudomonas should be treated with levofloxacin, moxifloxacin, ceftriaxone, or cefotaxime.

Table I. Suggested Antibiotic Treatment for Various Organisms

Table I.
Organism Antibiotics
Haemophilus influenzae Amoxicillin-clavulanate 500mg po three times daily or 875mg po twice dailyTrimethoprim-SulfamethaxazoleDS 1 tab po twice daily (resistance 7-10%) Fluoroquinolones: Moxifloxacin 400mg po daily, Levofloxacin 500mg po dailyMacrolides: Azithromycin 500mg po x 1, then 250mg daily x 4 days, Clarithromycin 500mg twice daily
Moraxella catarrhalis Trimethoprim-sulfamethoxazole DS 1 tab po dailyMacrolides: Erythromycin 500mg po four times daily,clarithomycin 500mg twice daily, Azithromycin 500mg x 1 then 250mg po daily x 4 days Tetracyclines: doxycycline 100mg po or IV twice dailyCephalosporins(oral): cefproxil 200-500 mg twice daily, cefpodoxime 200-400mg twice daily,cefuroxime 250-500mg twice daily, cefdinir 300mg twice daily Fluoroquinolones: moxifloxacin 400mg IV or po daily,levofloxacin 500mg IV or po dailyPenicillins: amoxicillin-clavulanate 875/125mg po twice daily
Streptococcus pneumoniae Amoxicillin 2-3 g po dailyDoxycycline100mg po twice dailyAmoxicillin 500-1000mg po three times dailyCefpodoxime 200mg po twice dailyPCN-resistant (PCN MIC >8):Levofloxacin 750mg po or IV dailyMoxifloxacin 400mg po or IV daily Ceftriaxone IVVancomycin 15mg/kg IV every 12 hoursLinezolid 600mg po or IV every 12 hours
Pseudomonas aeruginosa Use susceptibilities to guide final choices of antibiotic therapy. Piperacillin 3g IV every 4 hours or 4g IV every 6 hoursCefepime 1-2g IV every 8 hoursCeftazidime 2g IV every 8 hoursImipenem 1 g IV every 8 hoursMeropenem 1g IV every 8 hoursDoripenem 500mg IV every 8 hoursCiprofloxacin 400mg IV every 8 hours or 750mg po every 12 hoursAztreonam 2g IV every 8 hoursColistin 2.5mg/kg IV every 12 hours Polymixin B 0.75-1.25mg /kg IV every 12 hoursGentamicin 3mg/kg loading dose followed by 2mg/kg IV every 8 hours

2. Other key therapeutic modalities.

  • Oxygen therapy has an important role in COPD exacerbations. However, a patient with severe COPD who presents with hypercapnea and acidosis may develop suppression of the respiratory drive from uncontrolled oxygen therapy. Controlled oxygen administration should be tailored toward aiming for oxygen saturations of 88-92% in patients at risk for hypercapnea and 94-98% in patients without a history of previous respiratory acidosis. Arterial blood gases should be checked to determine response to treatment and changes in hypercarbia.

  • Short acting Beta-2 agonist bronchodilators improve shortness of breath in exacerbations. Anticholinergic agents may be effective in combination with a Beta-2 agonist in severe episodes, but evidence is uncertain. IV methylxanthines, such as theophylline, are second line agents for COPD exacerbations because of the limited evidence and the risk of drug interactions and adverse effects.

  • Systemic steroids improve outcomes in COPD exacerbations, as they improve dyspnea, FEV1, oxygenation, and health status; accelerate recovery of symptoms and lung function; and associated with fewer treatment failures and reduced length of hospital stay.

  • Noninvasive and invasive mechanical ventilation may be needed in cases of respiratory failure to provide support until the underlying cause of the respiratory failure can be treated.

  • Smoking cessation should be addressed in all patients still smoking.

What complications could arise as a consequence of chronic obstructive pulmonary disease?

  • Respiratory failure necessitating ICU admission is a serious consequence of a COPD exacerbation. Other sequelae of a COPD exacerbation include respiratory acidosis, hypoxemia, and altered mentation (from CO2 buildup).

  • COPD worsens over time, and it is difficult to predict this. Factors playing a role in the severity of COPD include continuation of smoking, being underweight, having other underlying medical illnesses, and lung function during exercise. Discussions about end of life care are important, especially before the patient becomes seriously ill.

  • The number of previous admissions for a COPD exacerbation, the severity of COPD, increased age, previous history of mechanical ventilation, poor nutritional status, high APACHE II score, and the development and severity of multiorgan system dysfunction have been identified as risk factors associated with increased mortality in patients admitted to an ICU.

How do you contract chronic obstructive pulmonary disease and how frequent is this disease?

COPD exacerbations are associated with increased airway and systemic inflammation. They are caused by complex interactions between the host, respiratory viruses, airway bacteria, and environmental pollution. They are frequently triggered by upper respiratory infections, especially during winter months. hese include infections with rhinoviruses,coronaviruses, respiratory syncytial virus, influenza, parainfluenza, and adenoviruses.

The role of bacteria in COPD exacerbations is not clear-cut. The most common bacterial pathogens isolated from patients with COPD exacerbations are Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae. It is controversial whether atypical bacteria, including chlamydia, legionella, and mycoplasma, are implicated in COPD exacerbations.

How can chronic obstructive pulmonary disease exacerbations be prevented?

The flu vaccine is recommended in all patients with COPD. One study showed a reduction in the risk for hospitalization for pneumonia and influenza and for mortality in COPD patients vaccinated for the flu. Pneumococcal vaccination has been shown to reduce the risk of pneumococcal pneumonia, but there is limited evidence of the effects in COPD exacerbations.

WHAT’S THE EVIDENCE for specific management and treatment recommendations?

Barnes, PJ. “Chronic obstructive pulmonary disease”. N Engl J Med. vol. 343. 2000. pp. 269-80.

Rabe, KF, Hurd, S, Anzueto, A. “Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary”. Am J Respir Crit Care Med. vol. 176. 2007. pp. 532-55.

Wedzicha, JA, Seemungal, TA. “COPD exacerbations: defining their cause and prevention”. Lancet. vol. 370. 2007. pp. 786-96.

Bourbeau, J. “Preventing hospitalization for COPD exacerbations”. Semin Respir Crit Care Med. vol. 31. 2010. pp. 313-20.

Hurst, JR, Vestbo, J, Anzueto, A. “Evaluation of COPD longitudinally to identify predictive surrogate endpoints (ECLIPSE) investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease”. N Engl J Med. vol. 363. 2010 Sep 16. pp. 1128-38.

Kamangar, N. “Chronic obstructive pulmonary disease”.

Understanding the impact of symptoms on the burden of COPD

  1. 1.

    Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J. 2006;27:397–412.

    • CAS
    • Article
    • Google Scholar
  2. 2.

    Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3:e442.

    • Article
    • PubMed Central
    • Google Scholar
  3. 3.

    Miravitlles M, Worth H, Soler Cataluna JJ, Price D, De Benedetto F, Roche N, et al. Observational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS study. Respir Res. 2014;15:122.

    • Article
    • PubMed Central
    • Google Scholar
  4. 4.

    Jones PW, Brusselle G, Dal Negro RW, Ferrer M, Kardos P, Levy ML, et al. Patient-centred assessment of COPD in primary care: experience from a cross-sectional study of health-related quality of life in Europe. Prim Care Respir J. 2012;21:329–36.

    • Article
    • Google Scholar
  5. 5.

    Kessler R, Partridge MR, Miravitlles M, Cazzola M, Vogelmeier C, Leynaud D, et al. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J. 2011;37:264–72.

    • CAS
    • Article
    • Google Scholar
  6. 6.

    Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2017. . Accessed 17 Nov 2016.

  7. 7.

    van der Molen T, Miravitlles M, Kocks JW. COPD management: role of symptom assessment in routine clinical practice. Int J Chron Obstruct Pulmon Dis. 2013;8:461–71.

    • Article
    • PubMed Central
    • Google Scholar
  8. 8.

    Kornmann O, Beeh KM, Beier J, Geis UP, Ksoll M, Buhl R. Newly diagnosed chronic obstructive pulmonary disease. Clinical features and distribution of the novel stages of the Global Initiative for Obstructive Lung Disease. Respiration. 2003;70:67–75.

  9. 9.

    Kaplan A, Marciniuk D, Bouchard J, Tessier L. Patient symptoms dictate how physicians behave in the early diagnosis of COPD . Prim Care Respir J. 2011;20:A6.

    • Article
    • Google Scholar
  10. 10.

    Lopez-Campos JL, Calero C, Quintana-Gallego E. Symptom variability in COPD: a narrative review. Int J Chron Obstruct Pulmon Dis. 2013;8:231–8.

    • Article
    • PubMed Central
    • Google Scholar
  11. 11.

    Miravitlles M, Anzueto A, Legnani D, Forstmeier L, Fargel M. Patient’s perception of exacerbations of COPD–the PERCEIVE study. Respir Med. 2007;101:453–60.

    • Article
    • Google Scholar
  12. 12.

    Monteagudo M, Rodríguez-Blanco T, Llagostera M, Valero C, Bayona X, Ferrer M, et al. Factors associated with changes in quality of life of COPD patients: a prospective study in primary care. Respir Med. 2013;107:1589–97.

    • Article
    • Google Scholar
  13. 13.

    Price D, Small M, Milligan G, Higgins V, Garcia Gil E, Estruch J. Impact of night-time symptoms in COPD: a real-world study in five European countries. Int J Chron Obstruct Pulmon Dis. 2013;8:595–603.

    • Article
    • PubMed Central
    • Google Scholar
  14. 14.

    Roche N, Chavannes NH, Miravitlles M. COPD symptoms in the morning: impact, evaluation and management. Respir Res. 2013;14:112.

    • Article
    • PubMed Central
    • Google Scholar
  15. 15.

    Tsiligianni I, Kocks J, Tzanakis N, Siafakas N, van der Molen T. Factors that influence disease-specific quality of life or health status in patients with COPD: a review and meta-analysis of Pearson correlations. Prim Care Respir J. 2011;20:257–68.

    • Article
    • Google Scholar
  16. 16.

    Doyle T, Palmer S, Johnson J, Babyak MA, Smith P, Mabe S, et al. Association of anxiety and depression with pulmonary-specific symptoms in chronic obstructive pulmonary disease. Int J Psychiatry Med. 2013;45:189–202.

    • Article
    • PubMed Central
    • Google Scholar
  17. 17.

    Partridge MR, Karlsson N, Small IR. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin. 2009;25:2043–8.

    • Article
    • Google Scholar
  18. 18.

    Roche N, Small M, Broomfield S, Higgins V, Pollard R. Real world COPD: association of morning symptoms with clinical and patient reported outcomes. COPD. 2013;10:679–86.

    • Article
    • Google Scholar
  19. 19.

    van Buul AR, Kasteleyn MJ, Chavannes NH, Taube C. Association between morning symptoms and physical activity in COPD: a systematic review. Eur Respir Rev. 2017;26: doi:10.1183/16000617.0033-2016.

  20. 20.

    Agusti A, Hedner J, Marin JM, Barbé F, Cazzola M, Rennard S. Night-time symptoms: a forgotten dimension of COPD. Eur Respir Rev. 2011;20:183–94.

    • CAS
    • Article
    • Google Scholar
  21. 21.

    Lange P, Marott JL, Vestbo J, Nordestgaard BG. Prevalence of night-time dyspnoea in COPD and its implications for prognosis. Eur Respir J. 2014;43:1590–8.

    • Article
    • Google Scholar
  22. 22.

    Donaldson GC, Wedzicha JA. The causes and consequences of seasonal variation in COPD exacerbations. Int J Chron Obstruct Pulmon Dis. 2014;9:1101–10.

    • Article
    • PubMed Central
    • Google Scholar
  23. 23.

    Jenkins CR, Celli B, Anderson JA, Ferguson GT, Jones PW, Vestbo J, et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. Eur Respir J. 2012;39:38–45.

    • CAS
    • Article
    • Google Scholar
  24. 24.

    Espinosa de los Monteros MJ, Peña C, Soto Hurtado EJ, Jareño J, Miravitlles M. Variability of respiratory symptoms in severe COPD. Arch Bronconeumol. 2012;48:3–7.

    • Article
    • Google Scholar
  25. 25.

    Miravitlles M, Worth H, Soler-Cataluna JJ, Price D, De Benedetto F, Roche N, et al. The relationship between 24-hour symptoms and COPD exacerbations and healthcare resource use: results from an observational study (ASSESS). COPD. 2016;13:561–8.

  26. 26.

    Kim YJ, Lee BK, Jung CY, Jeon YJ, Hyun DS, Kim KC, et al. Patient’s perception of symptoms related to morning activity in chronic obstructive pulmonary disease: the SYMBOL study. Korean J Intern Med. 2012;27:426–35.

    • Article
    • PubMed Central
    • Google Scholar
  27. 27.

    Stephenson JS, Cai Q, Mocarski M, Tan H, Doshi JA, Sullivan SD. Impact and factors associated with nighttime and early morning symptoms among patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:577–86.

    • Article
    • PubMed Central
    • Google Scholar
  28. 28.

    O’Hagan P, Chavannes NH. The impact of morning symptoms on daily activities in chronic obstructive pulmonary disease. Curr Med Res Opin. 2014;30:301–14.

    • Article
    • Google Scholar
  29. 29.

    Bateman ED, Chapman KR, Singh D, D’Urzo AD, Molins E, Leselbaum A, et al. Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respir Res. 2015;16:92.

    • Article
    • PubMed Central
    • Google Scholar
  30. 30.

    Miravitlles M, Ferrer J, Baro E, Lleonart M, Galera J. Differences between physician and patient in the perception of symptoms and their severity in COPD. Respir Med. 2013;107:1977–85.

    • Article
    • PubMed
    • Google Scholar
  31. 31.

    Gimeno-Santos E, Frei A, Steurer-Stey C, de Batlle J, Rabinovich RA, Raste Y, et al. Determinants and outcomes of physical activity in patients with COPD: a systematic review. Thorax. 2014;69:731–9.

    • Article
    • PubMed
    • PubMed Central
    • Google Scholar
  32. 32.

    Troosters T, Sciurba F, Battaglia S, Langer D, Valluri SR, Martino L, et al. Physical inactivity in patients with COPD, a controlled multi-center pilot-study. Respir Med. 2010;104:1005–11.

    • Article
    • PubMed
    • PubMed Central
    • Google Scholar
  33. 33.

    Watz H, Waschki B, Meyer T, Magnussen H. Physical activity in patients with COPD. Eur Respir J. 2009;33:262–72.

    • CAS
    • Article
    • PubMed
    • Google Scholar
  34. 34.

    Shrikrishna D, Patel M, Tanner RJ, Seymour JM, Connolly BA, Puthucheary ZA, et al. Quadriceps wasting and physical inactivity in patients with COPD. Eur Respir J. 2012;40:1115–22.

    • Article
    • PubMed
    • Google Scholar
  35. 35.

    Pleguezuelos E, Esquinas C, Moreno E, Guirao L, Ortiz J, Garcia-Alsina J, et al. Muscular dysfunction in COPD: systemic effect or deconditioning? Lung. 2016;194:249–57.

    • CAS
    • Article
    • PubMed
    • Google Scholar
  36. 36.

    Reardon JZ, Lareau SC, ZuWallack R. Functional status and quality of life in chronic obstructive pulmonary disease. Am J Med. 2006;119:32–7.

    • Article
    • PubMed
    • Google Scholar
  37. 37.

    Troosters T, van der Molen T, Polkey M, Rabinovich RA, Vogiatzis I, Weisman I, et al. Improving physical activity in COPD: towards a new paradigm. Respir Res. 2013;14:115.

    • Article
    • PubMed
    • PubMed Central
    • Google Scholar
  38. 38.

    Jones PW, Watz H, Wouters EF, Cazzola M. COPD: the patient perspective. Int J Chron Obstruct Pulmon Dis. 2016;11 Spec Iss:13–20.

    • PubMed
    • Google Scholar
  39. 39.

    Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Antó JM. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. Thorax. 2006;61:772–8.

    • CAS
    • Article
    • PubMed
    • PubMed Central
    • Google Scholar
  40. 40.

    Moy ML, Gould MK, Liu IA, Lee JS, Nguyen HQ. Physical activity assessed in routine care predicts mortality after a COPD hospitalisation. ERJ Open Res. 2016;2:eCollection 2016.

  41. 41.

    Dury R. COPD and emotional distress: not always noticed and therefore untreated. Br J Community Nurs. 2016;21:138–41.

    • Article
    • PubMed
    • Google Scholar
  42. 42.

    Pumar MI, Gray CR, Walsh JR, Yang IA, Rolls TA, Ward DL. Anxiety and depression-important psychological comorbidities of COPD. J Thorac Dis. 2014;6:1615–31.

    • PubMed
    • PubMed Central
    • Google Scholar
  43. 43.

    Willgoss TG, Yohannes AM. Anxiety disorders in patients with COPD: a systematic review. Respir Care. 2013;58:858–66.

    • PubMed
    • Google Scholar
  44. 44.

    Miravitlles M, Molina J, Quintano JA, Campuzano A, Pérez J, Roncero C. Factors associated with depression and severe depression in patients with COPD. Respir Med. 2014;108:1615–25.

    • Article
    • PubMed
    • Google Scholar
  45. 45.

    Martinez Rivera C, Costan Galicia J, Alcázar Navarrete B, Garcia-Polo C, Ruiz Iturriaga LA, Herrejón A, et al. Factors associated with depression in COPD: a multicenter study. Lung. 2016;194:335–43.

    • Article
    • PubMed
    • Google Scholar
  46. 46.

    Ng TP, Niti M, Tan WC, Cao Z, Ong KC, Eng P. Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. Arch Intern Med. 2007;167:60–7.

    • Article
    • PubMed
    • Google Scholar
  47. 47.

    Nunes DM, Mota RM, de Pontes Neto OL, Pereira ED, de Bruin VM, de Bruin PF. Impaired sleep reduces quality of life in chronic obstructive pulmonary disease. Lung. 2009;187:159–63.

    • Article
    • PubMed
    • Google Scholar
  48. 48.

    Valipour A, Lavie P, Lothaller H, Mikulic I, Burghuber OC. Sleep profile and symptoms of sleep disorders in patients with stable mild to moderate chronic obstructive pulmonary disease. Sleep Med. 2011;12:367–72.

    • Article
    • PubMed
    • Google Scholar
  49. 49.

    Cormick W, Olson LG, Hensley MJ, Saunders NA. Nocturnal hypoxaemia and quality of sleep in patients with chronic obstructive lung disease. Thorax. 1986;41:846–54.

    • CAS
    • Article
    • PubMed
    • PubMed Central
    • Google Scholar
  50. 50.

    McNicholas WT, Verbraecken J, Marin JM. Sleep disorders in COPD: the forgotten dimension. Eur Respir Rev. 2013;22:365–75.

    • Article
    • PubMed
    • Google Scholar
  51. 51.

    Scharf SM, Maimon N, Simon-Tuval T, Bernhard-Scharf BJ, Reuveni H, Tarasiuk A. Sleep quality predicts quality of life in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2010;6:1–12.

    • Article
    • PubMed
    • PubMed Central
    • Google Scholar
  52. 52.

    Omachi TA, Blanc PD, Claman DM, Chen H, Yelin EH, Julian L, et al. Disturbed sleep among COPD patients is longitudinally associated with mortality and adverse COPD outcomes. Sleep Med. 2012;13:476–83.

    • Article
    • PubMed
    • PubMed Central
    • Google Scholar
  53. 53.

    Spina G, Spruit MA, Alison J, Benzo RP, Calverley PM, Clarenbach CF et al. Analysis of nocturnal actigraphic sleep measures in patients with COPD and their association with daytime physical activity. Thorax. 2017;Epub ahead of print.

  54. 54.

    Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest. 2002;121:1434–40.

    • Article
    • PubMed
    • Google Scholar
  55. 55.

    Calverley PM. Cough in chronic obstructive pulmonary disease: is it important and what are the effects of treatment? Cough. 2013;9:17.

    • Article
    • PubMed
    • PubMed Central
    • Google Scholar
  56. 56.

    Burgel PR, Nesme-Meyer P, Chanez P, Caillaud D, Carré P, Perez T, et al. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest. 2009;135:975–82.

    • Article
    • PubMed
    • Google Scholar
  57. 57.

    Lindberg A, Sawalha S, Hedman L, Larsson LG, Lundback B, Ronmark E. Subjects with COPD and productive cough have an increased risk for exacerbations and death. Respir Med. 2015;109:88–95.

    • Article
    • PubMed
    • Google Scholar
  58. 58.

    Putcha N, Drummond MB, Connett JE, Scanlon PD, Tashkin DP, Hansel NN, et al. Chronic productive cough is associated with death in smokers with early COPD. COPD. 2014;11:451–8.

    • Article
    • PubMed
    • Google Scholar

About the author

Leave a Reply

Your email address will not be published. Required fields are marked *